Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy

作者：Ze-Xin Hu, Xiaoyang Xu, Ze Wang, Jintao Huang, Wan-Ci Li, Shuai Zhang, Jian Shen, Bin‐Yan Zhong, Xiaoli Zhu · 发表于：Journal of Hepatocellular Carcinoma · 年份：2023 · DOI：10.2147/jhc.s439660 · 被引用次数：13 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Cancer Immunotherapy and Biomarkers、Inflammatory Biomarkers in Disease Prognosis

Background: The CRAFITY (C-reactive protein and alpha-fetoprotein in immunotherapy) score has demonstrated prognostic significance in hepatocellular carcinoma (HCC) patients undergoing immunotherapy. The study aimed to validate accuracy of CRAFITY score on predicting prognosis for patients with HCC treated with transarterial chemoembolization (TACE) combined with PD-(L)1 inhibitors and molecular targeted therapy. Methods: Eighty-five HCC patients who underwent TACE in combination with molecular targeted therapy (MTT) and PD-(L)1 Inhibitors were consecutively enrolled from November 2019 to November 2022. Patients were divided into CRAFITY 0 score (n=32), CRAFITY 1 score (n=31), and CRAFITY 2 score (n=22), respectively. The primary outcomes were overall survival (OS) and progression-free survival (PFS), and the secondary outcomes included tumor response rate and treatment-related adverse events (TRAEs). Factors affecting survival were identified via Cox regression analysis. Results: The median overall survival (OS) for HCC patients with CRAFITY scores of 0, 1, and 2 was 33.4 months (95% confidence interval [CI]: 27.1– 39.7), 34.5 months (95% CI: 23.1– 45.9), and 24.2 months (95% CI: 13.9– 39.3), respectively, there were statistical differences among the three groups ( p < 0.05). The progression-free survival (PFS) was 14.1 months (95% CI: 10.0– 18.2), 14.1 months (95% CI: 9.0– 19.2), and 9.3 months (95% CI: 7.2– 11.4) for patients with CRAFITY scores of 1, 2, and 3, respectivel...